Fewer than a tenth of patients eligible to benefit from obesity jabs such as Wegovy have access to them, warns the World Health Organization as it releases its initial guidance on the drugs.
Given more than one billion people worldwide now living with obesity, it is calling for increased and just access to GLP-1 medication.
Per forecasts, more than two billion will be living with obesity by 2030 without intervention.
"Our new guidance acknowledges that excess weight is a long-term condition that can be managed with holistic and continuous care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major barriers to broad availability to the jabs that can aid individuals in losing considerable weight, notes the agency.
Weight-Loss Drug Scarcity
Despite the current most favorable case, the supply of such drugs might only reach about 100 million people – less than 10% of those who need them, per the WHO.
The advice encourages nations and manufacturers to expand access, by approaches like licensing agreements.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Injections Operate
GLP-1 drugs mimick a body's own hormone to delay gastric emptying, reduce hunger and boost feelings of fullness so individuals consume fewer calories.
People typically start to lose weight after several weeks of commencing the regular doses.
Research indicates users may regain a significant portion within a year of halting the drug, as their usual food cravings return.
Being overweight or obese increases your likelihood for developing medical conditions, such as diabetes, heart disease, stroke, and certain cancers.
Obesity concerns people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
